<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, ganciclovir is still the first treatment of choice for CMV infections. Letermovir has been approved for the prophylaxis of CMV infections in patients. Several new drugs were developed but still failed in the phase III and more clinical trials would be needed, including maribavir and brincidofovir [
 <xref rid="B37-viruses-12-00021" ref-type="bibr">37</xref>]. Valnoctamide, a neuroactive mood stabilizer which inhibits CMV infection in the developing brain and attenuates neurobehavioral dysfunctions, was shown to have anti-CMV potential [
 <xref rid="B38-viruses-12-00021" ref-type="bibr">38</xref>].
</p>
